The amount and route used in research
Tesamorelin Dosing Used in HIV Studies
Researchers gave tesamorelin beneath belly skin. You'll see the amount, the timing, and why a trial plan isn't your plan.
What plan did the tesamorelin studies test?
Both main studies focused on people with HIV. They didn't test a plan for everyone. Each used a 2 milligram shot beneath skin once daily.
These were Phase 3 studies, meaning large late tests. That plan became the approved HIV plan. It can't serve as advice for you.
The drug clears from blood within about half an hour. IGF-1, a liver-made hormone, stays raised longer. That change helped support one daily shot. You can't copy the plan.
These facts describe what researchers did. They aren't a dosing guide for you. Research-grade material belongs in a lab, not people.
What daily dose did the HIV trials use?
The extensively studied tesamorelin regimen is 2 mg subcutaneously once daily. That was the dose in both pivotal Phase 3 trials in HIV-associated lipodystrophy and the FDA-approved regimen [1][2][5]. A lower 1 mg/day arm has appeared in secondary studies, but the 2 mg once-daily paradigm is the one the visceral-fat efficacy data rest on.
Later reformulations changed the concentration and presentation rather than the underlying once-daily logic; across the program, the extensively validated paradigm remains 2 mg once daily by subcutaneous injection. These are doses administered to a specific HIV-positive clinical-trial population under medical supervision — described here as research context, not as a recommendation. No human dosing instruction is given on this site, and the material discussed is research-grade tesamorelin supplied for laboratory use, not the approved finished drug.
For Tesamorelin, the published regimens belong to supervised clinical care; prescription-only access belongs in a licensed, clinician-led setting such as Promise Peptides (mypromise.com), not in self-directed use of research-grade material.
Where did researchers place the tesamorelin shot?
Researchers put the shot beneath belly skin [5]. They didn't test another route. That's also the only approved route. No trial here used a pill, nose spray, or skin patch.
Your stomach would break tesamorelin apart. The medicine starts as dry powder. A medical liquid is added before use. The FDA label says it must stay cold.
That label sets a deadline after mixing [5]. This page doesn't give a safe storage time. Your clinic must follow its product label. These facts describe approved care, not self-use.
Why did studies give tesamorelin each day?
Your blood clears tesamorelin quickly. The formula in 1 paper uses an imagined removal volume of 1,060 liters an hour. You don't have or lose that blood. After 26-38 minutes, about half remains [11].
That seems too brief for a daily plan. IGF-1 provides the missing part. This liver-made hormone stays raised after tesamorelin leaves.
The rise lasted through the study day [11]. A changed drug end slows early breakdown [6]. That end is an altered drug part, not a coating.
The drug itself leaves quickly. Your hormone response lasts longer. That's what supported the study timing.
The mechanism page explains the timing for you. It can't turn a trial plan into advice.
Why isn't the trial dose a plan for you?
The 2 milligram daily plan was tested in HIV patients. Their organ fat was tied to HIV care [1][2]. You may not match that group. The trial can't say that you do.
No large trial set a dose for routine weight loss. None set one for anti-aging. FDA hasn't approved those non-HIV uses [5].
Organ fat returned after stopping. That happened in the 52-week work [2]. Researchers didn't find a lasting fixed course.
Keep the 2 milligram amount as study history. It isn't a plan for your body. Research-grade material isn't for human use.
The side effects and safety page explains the known harms.